This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Karo Pharma Future Growth

Future criteria checks 0/6

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	49.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Karo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OM:KARO - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2022	3,466	-190	-2,050	507	N/A
3/31/2022	3,231	-141	-1,546	572	N/A
12/31/2021	2,961	-17	-290	533	N/A
9/30/2021	2,921	63	-464	377	N/A
6/30/2021	2,861	2	-575	340	N/A
3/31/2021	2,802	49	-350	373	N/A
12/31/2020	2,883	82	-1,365	329	N/A
9/30/2020	2,811	86	-1,410	214	N/A
6/30/2020	2,575	87	-1,561	65	N/A
3/31/2020	2,274	55	-952	5	N/A
12/31/2019	1,901	9	122	107	N/A
9/30/2019	1,715	60	107	146	N/A
6/30/2019	1,667	117	353	385	N/A
3/31/2019	1,769	650	343	368	N/A
12/31/2018	1,615	657	299	318	N/A
9/30/2018	1,391	595	252	261	N/A
6/30/2018	1,132	551	82	92	N/A
3/31/2018	785	40	31	40	N/A
12/31/2017	658	15	26	34	N/A
9/30/2017	515	141	68	72	N/A
6/30/2017	463	133	76	84	N/A
3/31/2017	404	114	-10	60	N/A
12/31/2016	347	96	-106	-36	N/A
9/30/2016	308	-20	-119	-51	N/A
6/30/2016	232	-41	-125	-62	N/A
3/31/2016	151	-60	N/A	-94	N/A
12/31/2015	69	-78	N/A	-52	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if KARO's forecast earnings growth is above the savings rate (0.4%).

Earnings vs Market: Insufficient data to determine if KARO's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if KARO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if KARO's revenue is forecast to grow faster than the Swedish market.

High Growth Revenue: Insufficient data to determine if KARO's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KARO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company listing is no longer active

Karo Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Nasdaq Approves Karo Pharma's Application for De-Listing

Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.

Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).

Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Karo Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Karo Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others.

Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million.

Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)

Karo Pharma (STO:KARO) Has No Shortage Of Debt

Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)

Is Karo Pharma (STO:KARO) A Risky Investment?

Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO).

Independent Chairman of the Board Bo Hansen has left the company

First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021

Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million.

Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

New 90-day low: kr48.85

New 90-day low: kr51.10

Karo Pharma AB (publ) to Report First Half, 2021 Results on Jul 22, 2021

New 90-day low: kr58.10

New 90-day low: kr61.10

J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million.

Third quarter earnings released

EQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion.

Karo Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million.

Karo Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies